The North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market would witness market growth of 7.7% CAGR during the forecast period (2023-2030).
Anal, oral, and vaginal sex are all possible ways to spread Chlamydia trachomatis. It can also be transferred from a mother to a newborn child during childbirth. Women and young adults (15 to 24) are more likely to suffer from this medical condition. The prevalence of men and women experiencing infertility brought on by Chlamydia Trachomatis infection is generally increasing, therefore increasing internationally Artificial Insemination (AI) or Intrauterine Insemination (IUI) treatments.
The Chlamydia Trachomatis Test Model includes sub-segments for Chlamydia Trachomatis Nucleic Acid Amplification Tests (NAATs) and additional Chlamydia Trachomatis tests, such as Immunochromatography, Direct Fluorescent Antibody (DFA), Indirect Fluorescent Antibody (IFA), and Enzyme Linked Immuno Sorbent Assay (ELISA).
The two most prevalent reported sexually transmitted diseases (STI) in Canada are Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), according to a recent study issued by the Canadian government in May 2023. Rates of reported cases of CT increased by 33.1% between 2010 and 2019, whereas rates of NG climbed by 181.7%. The number of CT and NG cases reported in Canada in 2019 was 139,386 and 35,443, respectively. These numbers translate to rates of 370.8 and 94.3 per 100,000 people. In 2019, those from the Canadian territories (Yukon, Northwest Territories, and Nunavut) had the highest rates of CT, with 757.0, 1,901.0, and 3,876.8 cases per 100,000 individuals, respectively. Since 2010, the Northwest Territories and Nunavut have had the highest rates of NG, exceeding 1,000 cases per 100,000 persons in 2019. The regional market is anticipated to expand as STI cases are increasing gradually.
The US market dominated the North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $756.7 million by 2030. The Canada market is experiencing a CAGR of 10.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 9.2% during (2023 - 2030).
Based on Product, the market is segmented into Assays & Kits, and Instruments & Analyzers. Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Testing Type, the market is segmented into Lab Tests, and PoC Tests. Based on Technology, the market is segmented into Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market is Projected to reach USD 2.8 Billion by 2030, at a CAGR of 8.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, ZeptoMetrix LLC (Antylia Scientific), Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., Bayer AG, Qiagen N.V. and Siemens AG.
By Product
By End User
By Testing Type
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
